$149.09
0.66[0.44%]
Last update: 1:27PM Get Real Time Here
Alnylam Pharmaceuticals
(NASDAQ:ALNY)Alnylam Pharmaceuticals Stock (NASDAQ:ALNY), Analyst Ratings, Price Targets, Predictions
Alnylam Pharmaceuticals Inc has a consensus price target of $202.19, established from looking at the 100 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Chardan Capital, and Needham on May 7, 2024, May 3, 2024, and May 2, 2024. With an average price target of $275 between HC Wainwright & Co., Chardan Capital, and Needham, there's an implied 84.45% upside for Alnylam Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
Needham
BMO Capital
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Alnylam Pharmaceuticals
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/07/2024 | Buy Now | 168.29% | HC Wainwright & Co. | Patrick Trucchio | $395 → $400 | Maintains | Buy | Get Alert |
| 05/03/2024 | Buy Now | 50.92% | Chardan Capital | Keay Nakae | $225 → $225 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 34.15% | Needham | Joseph Stringer | → $200 | Reiterates | Buy → Buy | Get Alert |
| 03/27/2024 | Buy Now | 56.95% | BMO Capital | Kostas Biliouris | $234 → $234 | Maintains | Outperform | Get Alert |
| 03/05/2024 | Buy Now | 164.94% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 02/23/2024 | Buy Now | 0.61% | Cantor Fitzgerald | Olivia Brayer | $165 → $150 | Maintains | Neutral | Get Alert |
| 02/21/2024 | Buy Now | 57.62% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | 10.67% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/20/2024 | Buy Now | 57.62% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | 7.99% | Wells Fargo | Tiago Fauth | $171 → $161 | Maintains | Equal-Weight | Get Alert |
| 02/16/2024 | Buy Now | 52.26% | Citigroup | David Lebovitz | $237 → $227 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 57.62% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/16/2024 | Buy Now | 50.92% | Chardan Capital | Keay Nakae | $250 → $225 | Maintains | Buy | Get Alert |
| 02/16/2024 | Buy Now | 16.04% | Goldman Sachs | Salveen Richter | $230 → $173 | Downgrade | Buy → Neutral | Get Alert |
| 02/15/2024 | Buy Now | 34.15% | Needham | Joseph Stringer | → $200 | Reiterates | Buy → Buy | Get Alert |
| 02/15/2024 | Buy Now | 10.67% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/15/2024 | Buy Now | — | Wolfe Research | Andy Chen | — | Initiates | → Peer Perform | Get Alert |
| 02/14/2024 | Buy Now | 57.62% | RBC Capital | Luca Issi | → $235 | Reiterates | Outperform → Outperform | Get Alert |
| 02/13/2024 | Buy Now | 18.05% | Morgan Stanley | Michael Ulz | $184 → $176 | Maintains | Equal-Weight | Get Alert |
| 02/12/2024 | Buy Now | 10.67% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 02/01/2024 | Buy Now | 14.03% | JP Morgan | Jessica Fung | $150 → $170 | Maintains | Neutral | Get Alert |
| 01/22/2024 | Buy Now | 10.67% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 01/18/2024 | Buy Now | 10.67% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 12/15/2023 | Buy Now | 164.94% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 12/14/2023 | Buy Now | 10.67% | Cantor Fitzgerald | Olivia Brayer | → $165 | Reiterates | Neutral → Neutral | Get Alert |
| 12/14/2023 | Buy Now | 45.55% | Piper Sandler | Edward Tenthoff | $210 → $217 | Maintains | Overweight | Get Alert |
| 12/08/2023 | Buy Now | 14.7% | Wells Fargo | Tiago Fauth | → $171 | Initiates | → Equal-Weight | Get Alert |
| 11/15/2023 | Buy Now | 164.94% | HC Wainwright & Co. | Patrick Trucchio | → $395 | Reiterates | Buy → Buy | Get Alert |
| 11/03/2023 | Buy Now | 54.27% | RBC Capital | Luca Issi | $235 → $230 | Maintains | Outperform | Get Alert |
| 11/03/2023 | Buy Now | 22.74% | Morgan Stanley | Michael Ulz | $175 → $183 | Maintains | Equal-Weight | Get Alert |
FAQ
What is the target price for Alnylam Pharmaceuticals (ALNY)?
The latest price target for Alnylam Pharmaceuticals (NASDAQ: ALNY) was reported by HC Wainwright & Co. on May 7, 2024. The analyst firm set a price target for $400.00 expecting ALNY to rise to within 12 months (a possible 168.29% upside). 61 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Alnylam Pharmaceuticals (ALNY)?
The latest analyst rating for Alnylam Pharmaceuticals (NASDAQ: ALNY) was provided by HC Wainwright & Co., and Alnylam Pharmaceuticals maintained their buy rating.
When was the last upgrade for Alnylam Pharmaceuticals (ALNY)?
The last upgrade for Alnylam Pharmaceuticals Inc happened on May 5, 2023 when BMO Capital raised their price target to $250. BMO Capital previously had a market perform for Alnylam Pharmaceuticals Inc.
When was the last downgrade for Alnylam Pharmaceuticals (ALNY)?
The last downgrade for Alnylam Pharmaceuticals Inc happened on February 16, 2024 when Goldman Sachs changed their price target from $230 to $173 for Alnylam Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for Alnylam Pharmaceuticals (ALNY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Alnylam Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Alnylam Pharmaceuticals was filed on May 7, 2024 so you should expect the next rating to be made available sometime around May 7, 2025.
Is the Analyst Rating Alnylam Pharmaceuticals (ALNY) correct?
While ratings are subjective and will change, the latest Alnylam Pharmaceuticals (ALNY) rating was a maintained with a price target of $395.00 to $400.00. The current price Alnylam Pharmaceuticals (ALNY) is trading at is $149.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.